Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139

• Published in: mSphere Vol. 6; no. 4; p. e0011421
• Main Authors: Kamruzzaman, Mohammad, Kelly, Meagan, Charles, Richelle C, Harris, Jason B, Calderwood, Stephen B, Akter, Aklima, Biswas, Rajib, Kaisar, M Hasanul, Bhuiyan, Taufiqur R, Ivers, Louise C, Ternier, Ralph, Jerome, Jean-Gregory, Pfister, Hélene B, Lu, Xiaowei, Soliman, Sameh E, Ruttens, Bart, Saksena, Rina, Mečárová, Jana, Čížová, Alžbeta, Qadri, Firdausi, Bystrický, Slavomír, Kováč, Pavol, Xu, Peng, Ryan, Edward T
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 25.08.2021
• Subjects: Adolescent; Adult; Aged; Animals; Antibodies, Bacterial - blood; Child; Cholera - immunology; Cholera - prevention & control; Cholera Vaccines - administration & dosage; Cholera Vaccines - immunology; Convalescence; Disease Models, Animal; Female; Hospitalization - statistics & numerical data; Humans; Immunoglobulin A - blood; Immunoglobulin G - blood; Immunoglobulin M - blood; Male; Mice; Middle Aged; O Antigens - immunology; Research Article; Vaccination; Vaccines; Vaccines, Combined - administration & dosage; Vaccines, Combined - immunology; Vaccines, Conjugate - administration & dosage; Vaccines, Conjugate - immunology; Vaccines, Conjugate - standards; Vibrio cholerae O139 - immunology; Young Adult; synthetic saccharides; O-specific polysaccharide; conjugate vaccine; Vibrio cholerae O139; immunity; immune response
• ISSN: 2379-5042; 2379-5042
• DOI: 10.1128/mSphere.00114-21

Cholera caused by Vibrio cholerae O139 could reemerge, and proactive development of an effective O139 vaccine would be prudent. To define immunoreactive and potentially immunogenic carbohydrate targets of Vibrio cholerae O139, we assessed immunoreactivities of various O-specific polysaccharide (OSP)-related saccharides with plasma from humans hospitalized with cholera caused by O139, comparing responses to those induced in recipients of a commercial oral whole-cell killed bivalent (O1 and O139) cholera vaccine (WC-O1/O139). We also assessed conjugate vaccines containing selected subsets of these saccharides for their ability to induce protective immunity using a mouse model of cholera. We found that patients with wild-type O139 cholera develop IgM, IgA, and IgG immune responses against O139 OSP and many of its fragments, but we were able to detect only a moderate IgM response to purified O139 OSP-core, and none to its fragments, in immunologically naive recipients of WC-O1/O139. We found that immunoreactivity of O139-specific polysaccharides with antibodies elicited by wild-type infection markedly increase when saccharides contain colitose and phosphate residues, that a synthetic terminal tetrasaccharide fragment of OSP is more immunoreactive and protectively immunogenic than complete OSP, that native OSP-core is a better protective immunogen than the synthetic OSP lacking core, and that functional vibriocidal activity of antibodies predicts protection in our model but depends on capsule thickness. Our results suggest that O139 OSP-specific responses are not prominent following vaccination with a currently available oral cholera vaccine in immunologically naive humans and that vaccines targeting V. cholerae O139 should be based on native OSP-core or terminal tetrasaccharide. Cholera is a severe dehydrating illness of humans caused by Vibrio cholerae serogroup O1 or O139. Protection against cholera is serogroup specific, and serogroup specificity is defined by O-specific polysaccharide (OSP). Little is known about immunity to O139 OSP. In this study, we used synthetic fragments of the O139 OSP to define immune responses to OSP in humans recovering from cholera caused by V. cholerae O139, compared these responses to those induced by the available O139 vaccine, and evaluated O139 fragments in next-generation conjugate vaccines. We found that the terminal tetrasaccharide of O139 is a primary immune target but that the currently available bivalent cholera vaccine poorly induces an anti-O139 OSP response in immunologically naive individuals.